search
Back to results

Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery

Primary Purpose

Orthognathic Relapse

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Botox
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Orthognathic Relapse focused on measuring mandibular advancement, orthognathic relapse

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients need bilateral sagittal split osteotomy for correction of skeletal class II malocclusion (mandibular retrognathism).
  • Age of the patient above 18 years.
  • All patients are free from any systemic disease that may affect normal bone healing.

Exclusion Criteria:

  • Patient with history of facial bone trauma, cleft lip or palate.
  • Intra-bony lesions or infections that may interfere with surgery.
  • Previous orthognathic surgeries.
  • Patients with relative contraindications to (BTX) injection such as pregnancy, lactation, neuromuscular diseases (e.g., myasthenia gravis), motor neuron disease, allergy to any of the components of (BTX).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Botox injection group

    placebo group

    Arm Description

    Botox injection in anterior belly of digastric before mandibular advancement orthognathic surgery

    no injection before surgery

    Outcomes

    Primary Outcome Measures

    relapse
    relapse in mandibular advancement

    Secondary Outcome Measures

    Full Information

    First Posted
    October 6, 2022
    Last Updated
    October 8, 2022
    Sponsor
    Cairo University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05573581
    Brief Title
    Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery
    Official Title
    Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery (Randomized Controlled Trial)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2023 (Anticipated)
    Primary Completion Date
    January 2025 (Anticipated)
    Study Completion Date
    January 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Cairo University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The purpose of this study is to test whether Botox injection in anterior belly of digastric muscle in BSSO for mandibular advancement surgery could reduce the tendency of postoperative relapse. Research question: (P) In patient has skeletal class II mandibular retrognathism, (I) will Botox injection in anterior belly of digastric. (O) Affect the relapse of the mandible after mandibular advancement orthognathic surgery? Participants will be undergo Botox injection in anterior belly of digastric and bilateral sagittal split surgery
    Detailed Description
    In the intervention group: Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extra oral approach in 4 point. Intra-operative procedures: Access through a vestibular Sagittal split incision for mandible will be carried out. Dissection and reflection to reach the bone will be carried out. The cutting guide of the mandible will be placed onto the exposed bony surface and manipulated to the best fit. Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side. Then, a reciprocating saw will be used to perform the planned bilateral sagittal split osteotomy. After adequate mandibular mobilization and removal of bony interferences, the mandible will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws. In Bi-max surgery the maxillary cutting guide will be fixed in the same manner and Lefort I osteotomy will be carried out. After adequate mobilization, the maxilla will be repositioned by the patient specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws. All incisions were closed with 4-0 resorbable sutures.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Orthognathic Relapse
    Keywords
    mandibular advancement, orthognathic relapse

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Model Description
    randomized controlled trial
    Masking
    Care ProviderOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    10 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Botox injection group
    Arm Type
    Experimental
    Arm Description
    Botox injection in anterior belly of digastric before mandibular advancement orthognathic surgery
    Arm Title
    placebo group
    Arm Type
    No Intervention
    Arm Description
    no injection before surgery
    Intervention Type
    Drug
    Intervention Name(s)
    Botox
    Other Intervention Name(s)
    botulinum toxin type A
    Intervention Description
    Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
    Primary Outcome Measure Information:
    Title
    relapse
    Description
    relapse in mandibular advancement
    Time Frame
    6 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients need bilateral sagittal split osteotomy for correction of skeletal class II malocclusion (mandibular retrognathism). Age of the patient above 18 years. All patients are free from any systemic disease that may affect normal bone healing. Exclusion Criteria: Patient with history of facial bone trauma, cleft lip or palate. Intra-bony lesions or infections that may interfere with surgery. Previous orthognathic surgeries. Patients with relative contraindications to (BTX) injection such as pregnancy, lactation, neuromuscular diseases (e.g., myasthenia gravis), motor neuron disease, allergy to any of the components of (BTX).

    12. IPD Sharing Statement

    Learn more about this trial

    Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery

    We'll reach out to this number within 24 hrs